SynthesisFrontiers in oncology2021

Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.

Qingyu Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.